S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
MarketsFN
Home/Hedge Funds/Baker Bros Advisors/Q4 2025

Baker Bros Advisors

Period: Q4 2025 · Filed: 2026-02-17
View on SEC EDGAR
AUM
$17.08B
Total portfolio value
Positions
86
Reported securities
Top Holding
INCY
17.8% $3.04B
QoQ Changes
+8 / -8
new · exited
⚠️13F Filing Disclosure

AUM figures shown are calculated by summing the reported market value of all positions in SEC 13F-HR filings — not the fund's actual assets under management.

  • Excludes cash, bonds, private equity, short positions, and foreign-listed stocks not required to be reported.
  • For PUT and CALL options, the reported Value is the notional value of the underlying shares — not the option premium paid. This significantly overstates the actual capital at risk.
  • Actual fund AUM is typically higher and includes strategies, instruments, and positions that never appear in a 13F.
  • 13F filings cover institutional managers with ≥$100M in 13F securities. Positions reflect end-of-quarter holdings, disclosed up to 45 days after the period ends.

Data sourced from SEC EDGAR. This tracker is for informational purposes only and does not constitute investment advice.

Portfolio Holdings

Top 30 positions

⚠️ Performance % calculated from filing date ( 2026-02-17) shown is the underlying stock price movement — not the derivative's P&L.
TickerIssuerNotionalPort %@ FilingNow (EOD)Since FilingAllocation
INCYIncyte Corporation$3.04B17.78%$98.77$116.86+18.3%
17.8%
ONCBeOne Medicines Ltd.$2.67B15.65%$303.81$297.65-2.0%
15.7%
MDGLMadrigal Pharmaceuticals, Inc.$1.25B7.30%$582.34$528.10-9.3%
7.3%
INSMInsmed Incorporated$1.15B6.72%$174.04$111.60-35.9%
6.7%
ACADACADIA Pharmaceuticals Inc.$1.15B6.71%$26.71$25.97-2.8%
6.7%
CELCCelcuity Inc.$789.5M4.62%$99.74$107.95+8.2%
4.6%
RVMDRevolution Medicines, Inc.$753.1M4.41%$79.65$189.24+137.6%
4.4%
KYMRKymera Therapeutics, Inc.$673.6M3.94%$77.81$113.51+45.9%
3.9%
SMMTSummit Therapeutics Inc.$636.5M3.73%$17.49$15.42-11.8%
3.7%
RYTMRhythm Pharmaceuticals, Inc.$599.9M3.51%$107.04$114.17+6.7%
3.5%
KODKodiak Sciences Inc.$556.9M3.26%$27.96$38.54+37.8%
3.3%
PRAXPraxis Precision Medicines, Inc.$332.0M1.94%$294.74$318.52+8.1%
1.9%
ALKSAlkermes plc$280.1M1.64%$27.98$54.58+95.1%
1.6%
GRALGRAIL, Inc.$178.5M1.05%$85.59$69.11-19.3%
1.1%
EWTXEdgewise Therapeutics, Inc.$163.2M0.96%$24.82$39.56+59.4%
1.0%
ARWRArrowhead Pharmaceuticals, Inc.$144.4M0.85%$66.39$83.99+26.5%
0.8%
IONSIonis Pharmaceuticals, Inc.$141.8M0.83%$79.11$81.80+3.4%
0.8%
IMVTImmunovant, Inc.$138.7M0.81%$25.42$38.79+52.6%
0.8%
IMTXImmatics N.V.$127.0M0.74%$10.50$9.95-5.2%
0.7%
IDYAIDEAYA Biosciences, Inc.$125.1M0.73%$34.57$37.65+8.9%
0.7%
ROIVRoivant Sciences Ltd.$120.5M0.71%$21.70$35.13+61.9%
0.7%
ABVXAbivax S.A.$118.1M0.69%$134.85$144.65+7.3%
0.7%
KNSAKiniksa Pharmaceuticals International, plc$116.6M0.68%$41.25$64.53+56.4%
0.7%
REPLReplimune Group, Inc.$107.4M0.63%$9.72$11.58+19.1%
0.6%
STOKStoke Therapeutics, Inc.$105.9M0.62%$31.74$32.70+3.0%
0.6%
GPCRStructure Therapeutics Inc.$99.6M0.58%$69.55$53.45-23.1%
0.6%
ABCLAbCellera Biologics Inc.$94.1M0.55%$3.42$8.11+137.1%
0.6%
NRIXNurix Therapeutics, Inc.$88.4M0.52%$18.97$23.97+26.4%
0.5%
IMCRImmunocore Holdings plc$80.6M0.47%$34.71$32.50-6.4%
0.5%
BCYCBicycle Therapeutics plc$77.1M0.45%$7.08$4.35-38.6%
0.5%

Quarter-on-Quarter Activity

Q4 2025 vs. Q3 2025

New Positions (8)

TickerIssuerNotional
TERNTerns Pharmaceuticals, Inc.$38.4M
JBIOJade Biosciences, Inc.$25.3M
BCRXBioCryst Pharmaceuticals, Inc.$22.0M
CNTACentessa Pharmaceuticals plc$16.8M
DYNDyne Therapeutics, Inc.$15.9M
ABSIAbsci Corporation$7.5M
RCUSArcus Biosciences, Inc.$6.4M
MPLTMapLight Therapeutics, Inc.$6.4M

Exited Positions (8)

TickerIssuerNotional
MRUSMerus N.V.$54.1M
NTLAIntellia Therapeutics, Inc.$47.4M
RNAMAvidity Biosciences, Inc.$27.2M
PCVXVaxcyte, Inc.$23.1M
CDTXCidara Therapeutics, Inc.$21.8M
AKROAkero Therapeutics, Inc.$15.4M
ACLXArcellx, Inc.$13.7M
VKTXViking Therapeutics, Inc.$9.6M

Increased (8)

TickerIssuerNotionalShares ΔSince Filing
CTNMContineum Therapeutics, Inc.$15.3M+1729.3%
TECXTectonic Therapeutic, Inc.$17.3M+803.4%
CRNXCrinetics Pharmaceuticals, Inc.$65.1M+488.9%
IONSIonis Pharmaceuticals, Inc.$104.7M+216.1%+3.4%
ELVNEnliven Therapeutics, Inc.$1.8M+136.3%
VTYXVentyx Biosciences, Inc.$18.0M+129.6%
KALAKALA BIO, Inc.$-0.5M+83.1%
TARAProtara Therapeutics, Inc.$2.8M+81.0%

Trimmed (7)

TickerIssuerNotionalShares ΔSince Filing
SANASana Biotechnology, Inc.$-6.0M-84.7%
ARGXargenx SE$-6.7M-33.3%
STOKStoke Therapeutics, Inc.$-3.0M-28.0%+3.0%
GLUEMonte Rosa Therapeutics, Inc.$31.7M-11.6%
EWTXEdgewise Therapeutics, Inc.$44.7M-10.0%+59.4%
GPCRStructure Therapeutics Inc.$56.1M-7.9%-23.1%
INSMInsmed Incorporated$182.0M-1.7%-35.9%
Back to Hedge Funds